Phase Ib Trial of Low-Dose Selinexor (KPT-330) in Combination With Choline Salicylate (CS) for the Treatment of Patients With Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasms, or Multiple Myeloma
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Choline salicylate (Primary) ; Selinexor (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 04 Oct 2023 Planned End Date changed from 15 Dec 2024 to 15 Dec 2025.
- 04 Oct 2023 Planned primary completion date changed from 15 Dec 2023 to 15 Dec 2024.
- 24 Feb 2022 Diffuse Large-B-cell lymphoma (DLBCL) and Mantle cell Lymphoma (MCL) have been removed from indications and histiocytic/dendritic cell neoplasms have been added.